Efficacy and safety of JR-051, a biosimilar of agalsidase beta, in patients with Fabry disease; results of a multicenter, open-label phase 3 study in Japan
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI